Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Public ClinicalTrials.gov record NCT00513474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Rasburicase to Prevent Graft -Versus-Host Disease
Study identification
- NCT ID
- NCT00513474
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Massachusetts General Hospital
- Other
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Interventions
- allogeneic hematopoietic stem cell transplantation Procedure
- allopurinol Drug
- busulfan Drug
- cyclophosphamide Drug
- cyclosporin-A Drug
- etoposide Drug
- fludarabine Drug
- methotrexate Drug
- peripheral blood stem cell transplantation Procedure
- rasburicase Drug
- sirolimus Drug
- tacrolimus Drug
- total-body irradiation Radiation
Procedure · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Feb 11, 2013
- Completion
- Feb 11, 2013
- Last update posted
- May 24, 2017
2008 – 2013
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114-2617 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00513474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2017 · Synced Apr 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00513474 live on ClinicalTrials.gov.